Abstract
Human primary thyroid follicular epithelial cells were transfected with a plasmid containing an origin-defective SV40 genome (SVori-) to produce several immortal cell lines. Two of the 10 cell lines analysed expressed specific features of thyroid epithelial function (iodide-trapping and thyroglobulin production). These two lines were characterised in detail and found to be growth factor-independent, capable of anchorage-independent growth at low frequency but non-tumorigenic in nude mice. These differentiated, These differentiated, partially transformed cell lines were shown to be suitable for gene transfer at high frequency using simple coprecipitation techniques.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lemoine, N., Mayall, E., Jones, T. et al. Characterisation of human thyroid epithelial cells immortalised in vitro by simian virus 40 DNA transfection. Br J Cancer 60, 897–903 (1989). https://doi.org/10.1038/bjc.1989.387
Issue Date:
DOI: https://doi.org/10.1038/bjc.1989.387
This article is cited by
-
Morphologic and genomic changes of thyroid cancer cell lines exposed to conditions of simulated microgravity
npj Microgravity (2024)
-
Characterization of metabolic reprogramming by metabolomics in the oncocytic thyroid cancer cell line XTC.UC1
Scientific Reports (2023)
-
FAM83B is involved in thyroid cancer cell differentiation and migration
Scientific Reports (2022)
-
Nickel Sulfate Induces Autophagy in Human Thyroid Follicular Epithelial Cells
Biological Trace Element Research (2022)
-
Hsa_circRNA_102002 facilitates metastasis of papillary thyroid cancer through regulating miR-488-3p/HAS2 axis
Cancer Gene Therapy (2021)